The 67th Annual Meeting of the American Society of Hematology (ASH) was held from December 6 to 9, 2025, in Orlando, bringing together the latest global advances in hematology research and clinical practice. At this year’s meeting, the team led by Professor Hu Kai from Beijing Gaobo Hospital presented seven studies focusing on CAR-T cell therapy across different types of relapsed/refractory lymphoma, including B-cell lymphoma, central nervous system lymphoma, T-cell lymphoma, as well as combined strategies involving CAR-T therapy and hematopoietic stem cell transplantation. These studies provide important evidence supporting the further development of individualized treatment strategies. Oncology Frontier – Hematology Frontier invited Professor Hu Kai to provide an in-depth interpretation of these key findings and their clinical significance.

The 67th Annual Meeting of the American Society of Hematology (ASH) was held grandly in Orlando from December 6 to 9, 2025, bringing together the latest research and clinical advances…

Despite the remarkable progress achieved with single-target CAR-T therapy in the treatment of relapsed/refractory large B-cell lymphoma (R/R LBCL), a proportion of patients still experience suboptimal responses or relapse after treatment. At the 67th Annual Meeting of the American Society of Hematology (ASH), a study led by Professor Wang Liang from Beijing Tongren Hospital, Capital Medical University, was selected for an oral presentation, reporting impressive results from a phase II clinical trial of dual-target CD19/CD22 CAR-T cell therapy in R/R LBCL. The findings attracted wide attention. Hematology Frontier invited Professor Wang Liang for an in-depth discussion of the innovative aspects of this study, offering valuable insights for future optimization of R/R LBCL treatment strategies and research directions.